AbbVie Completes Acquisition of Capstan Therapeutics

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.

Regeneron Acquires Checkmate Pharmaceuticals

April 19, 2022

Biotechnology

Regeneron Pharmaceuticals agreed to acquire Checkmate Pharmaceuticals in an all-cash transaction valuing Checkmate at approximately $250 million (at $10.50 per share). The acquisition brings Checkmate's lead investigational immune activator, vidutolimod (a VLP-delivered TLR9 agonist), into Regeneron’s immuno-oncology portfolio to accelerate development and enable combination strategies across tumor types.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Turnspire Capital Partners Completes Acquisition of Pharmachem Innovations from Ashland

September 3, 2024

Food & Beverage

Turnspire Capital Partners has acquired Pharmachem Innovations, the former nutraceuticals business of Ashland Inc., creating an independent nutraceuticals platform. Pharmachem — a provider of proprietary nutrition ingredients, custom formulation and contract manufacturing with ~500 employees across facilities in New Jersey, Utah and Tamaulipas, Mexico — will be led by Executive Chairman Maurice Murphy and Interim CEO Jeff Rogers as Turnspire pursues operational growth opportunities.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.